Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR, cetuximab and panitumumab, in metastatic colon cancer [7] and BRAF V600E mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [8]. The gene discussed is BRAF; the disease is metastatic melanoma.